We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+3.46%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.35B
AUM Growth
-$141M
Cap. Flow
+$96.9M
Cap. Flow %
2.89%
Top 10 Hldgs %
41.69%
Holding
77
New
11
Increased
22
Reduced
20
Closed
9

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$68M
2
APLS
Apellis Pharmaceuticals
APLS
+$67.9M
3
TGTX icon
TG Therapeutics
TGTX
+$45.8M
4
KRRO icon
Korro Bio
KRRO
+$42.6M
5
AXSM icon
Axsome Therapeutics
AXSM
+$40.6M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$108M
2
GERN icon
Geron
GERN
+$68.2M
3
APGE icon
Apogee Therapeutics
APGE
+$64.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.5M
5
TRML
Tourmaline Bio
TRML
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVVD icon
51
Invivyd
IVVD
$160M
$12M 0.36%
10,953,937
– –
ZURA icon
52
Zura Bio
ZURA
$504M
$11.5M 0.34%
3,283,783
+760,783
+30% +$3.1M
KURA icon
53
Kura Oncology
KURA
$793M
$7.92M 0.24%
+384,756
New +$7.91M
CYTK icon
54
Cytokinetics
CYTK
$10.6B
$7.18M 0.21%
+132,495
New +$8M
RGLS
55
DELISTED
Regulus Therapeutics
RGLS
$5.82M 0.17%
3,262,564
-4,002
-0.1% -$9.29K
ANRO icon
56
Alto Neuroscience
ANRO
$1.04B
$5.47M 0.16%
511,686
-88,314
-15% -$1.15M
AGEN
57
Agenus
AGEN
$276M
$5.25M 0.16%
313,359
-1,271,518
-80% -$15.4M
ALLK
58
DELISTED
Allakos
ALLK
$5M 0.15%
5,000,000
– –
SYRS
59
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.27M 0.13%
828,485
– –
RLMD icon
60
Relmada Therapeutics
RLMD
$540M
$3.7M 0.11%
1,234,773
-5,261
-0.4% -$19K
EWTX icon
61
Edgewise Therapeutics
EWTX
$4.28B
$3.36M 0.1%
+186,386
New +$3.25M
SRRK icon
62
Scholar Rock
SRRK
$5.88B
$3.1M 0.09%
372,559
-307,441
-45% -$3.76M
RPTX
63
DELISTED
Repare Therapeutics
RPTX
$2.98M 0.09%
904,261
-1,780,083
-66% -$6.35M
COGT icon
64
Cogent Biosciences
COGT
$6.76B
$2.6M 0.08%
308,235
-7,765
-2% -$58.9K
VIGL
65
DELISTED
Vigil Neuroscience
VIGL
$2.39M 0.07%
597,215
-997,716
-63% -$3.41M
ALGS icon
66
Aligos Therapeutics
ALGS
$26.3M
$2.14M 0.06%
244,111
– –
MGX icon
67
Metagenomi Therapeutics
MGX
$45.6M
$1.9M 0.06%
466,232
– –
NMRA icon
68
CALL
Neumora Therapeutics
NMRA
$306M
$1.77M 0.05%
+180,500
New +$1.87M
ANAB icon
69
AnaptysBio
ANAB
$1.54B
– –
-529,452
Closed -$11.9M
MRSN
70
DELISTED
Mersana Therapeutics
MRSN
– –
-23,187
Closed -$2.6M
NMRA icon
71
Neumora Therapeutics
NMRA
$306M
– –
-1,000,000
Closed -$10.3M
NUVL
72
DELISTED
Nuvalent
NUVL
– –
-274,512
Closed -$20.6M
PACB icon
73
Pacific Biosciences
PACB
$435M
– –
-7,000,000
Closed -$26.3M
PRME icon
74
Prime Medicine
PRME
$547M
– –
-303,716
Closed -$2.13M
RARE icon
75
Ultragenyx Pharmaceutical
RARE
$2.46B
– –
-167,784
Closed -$7.83M
1 2
3
4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Deep Track Capital held 77 positions worth $3.35B, down 4% from $3.49B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deep Track Capital's Q2 2024 filing shows 11 new, 22 increased, 20 reduced and 9 closed positions. Its largest new stake was TG Therapeutics: 2,870,131 shares worth $51.1M. The largest sale was Insmed, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Deep Track Capital's largest Q2 2024 buy was TG Therapeutics: 2,870,131 shares worth $51.1M.
  • Deep Track Capital added most to Immunovant in Q2 2024, an estimated $68M increase.
  • Deep Track Capital's biggest Q2 2024 reduction was Insmed, cutting an estimated $108M.
  • Deep Track Capital fully exited Tourmaline Bio in Q2 2024, selling an estimated $36.5M.
  • Deep Track Capital's ten largest holdings make up 42% of its $3.35B portfolio in Q2 2024.
  • Deep Track Capital opened 11 new positions and closed 9 in Q2 2024.
  • Deep Track Capital's portfolio value fell 4% quarter-over-quarter to $3.35B.

Based on Deep Track Capital's 13F filing for Q2 2024, filed 14 Aug 2024.